Crossmark

EANM guideline on the role of 2-[18F]FDG PET/CT in diagnosis, staging, prognostic value, therapy assessment and restaging of ovarian cancer, endorsed by the American College of Nuclear Medicine (ACNM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the International Atomic Energy Agency (IAEA)

Crossref DOI link: https://doi.org/10.1007/s00259-021-05450-9

Published Online: 2021-07-03

Published Print: 2021-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Delgado Bolton, Roberto C. https://orcid.org/0000-0002-8071-6513
Aide, Nicolas https://orcid.org/0000-0001-9207-0847
Colletti, Patrick M. https://orcid.org/0000-0001-9625-8046
Ferrero, Annamaria https://orcid.org/0000-0002-2909-3699
Paez, Diana https://orcid.org/0000-0001-9268-0979
Skanjeti, Andrea https://orcid.org/0000-0002-3132-7116
Giammarile, Francesco https://orcid.org/0000-0002-0550-7893
License Information

Text and Data Mining valid from 2021-07-03

Version of Record valid from 2021-07-03
More Information

Article History

Received: 5 May 2021

Accepted: 3 June 2021

First Online: 3 July 2021

Declarations

:

: This article does not contain any studies with human participants performed by any of the authors.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below